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Available online 29 April 2016Successfully translating anti-cancer nanomedicines from pre-clinical proof of concept to demonstration of
therapeutic value in the clinic is challenging. Having made signiﬁcant advances with drug delivery technologies,
we must learn from other areas of oncology drug development, where patient stratiﬁcation and target-driven
design have improved patient outcomes. We should evolve our nanomedicine development strategies to build
the patient and disease into the line of sight from the outset. The success of small molecule targeted therapies has
been signiﬁcantly improved by employing a speciﬁc decision-making framework, such as AstraZeneca's 5R princi-
ple: right target/efﬁcacy, right tissue/exposure, right safety, right patient, and right commercial potential. With ap-
propriate investment and collaboration to generate a platform of evidence supporting the end clinical application, a
similar framework can be established for enhancing nanomedicine translation and performance. Building informa-
tive data packages to answer these questions requires the following: (I) an improved understanding of the hetero-
geneity of clinical cancers and of the biological factors inﬂuencing the behaviour of nanomedicines in patient
tumours; (II) a transition from formulation-driven research to disease-driven development; (III) the implementa-
tion of more relevant animal models and testing protocols; and (IV) the pre-selection of the patients most likely
to respond to nanomedicine therapies. These challenges must be overcome to improve (the cost-effectiveness of)
nanomedicine development and translation, and they are key to establishing superior therapies for patients.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Nanomedicines have been investigated for the targeted delivery of
drugs to treat a large variety of diseases. This industry perspective
focusses on oncology-based nanomedicinal therapeutics only, as they
receive about two-thirds of the research attention [1]. The concept
that nanomedicines aim to improve the therapeutic index of anti-
cancer drugs by modifying their pharmacokinetics and tissue distribu-
tion to improve delivery to the site of action is well known and has
also been demonstrated clinically. Designed to exploit the enhanced
permeability and retention (EPR) effect [2–3], liposomal doxorubicin
(Doxil™/Caelyx™) was the ﬁrst anti-cancer nanomedicine approved
by the FDA in 1995 [4–7]. Doxil™/Caelyx™ achieves a differential
distribution of doxorubicin versus the free drug and is now approved
for several indications based on improved safety with equivalent or su-
perior efﬁcacy versus standard therapies [8]. In patients, Doxil™ has
achieved a nearly 300-fold increase in area under the curve, relative to
free doxorubicin [4], although this includes free (bioavailable) and
liposome-encapsulated (non-bioavailable) doxorubicin.
Other nanomedicines approved for clinical use for cancer treatment
include: Myocet™, DaunoXome™, Depocyt™, Abraxane™, Genexol-
PM™, and, mostly recently, Onivyde™ (see Table 1). The approval of
newnanomedicines has been based primarily on improving therapeutic
beneﬁt by enhancing safety, with patient survival being equivalent to
that resulting from the use of standard treatments [9]. The signiﬁcant
anti-cancer activity demonstrated pre-clinically by many novel
nanomedicines has yet to be recapitulated clinically [10], and, as a re-
sult, the development of the marketed nanomedicines has often been
slow. Although valuable, the lack of or limited gain in overall survival
challenges the ﬁeld to improve patient survival further withmore effec-
tive nanomedicine-based therapies. Many of the key opinion leaders in
the nanomedicine ﬁeld have written excellent articles detailing the
challenges facing the successful development of novel nanomedicinal
therapeutics and suggestions to overcome these hurdles, including
refs. [11–16], amongst others.
At AstraZeneca, improved success in translating new drug projects
to the clinic has been achieved by evaluating a drug's 5Rs: ‘right tar-
get/efﬁcacy’, ‘right tissue/exposure’, ‘right patients’, ‘right safety’, and
‘right commercial potential’ [17]. This means that the pre-clinical data,
at a minimum, must be consistent with the agent being able to achieve
target engagement or inhibition in man—through the appropriate level
of drug exposure at the target tissue, as determined from in vitro and
in vivo screening. Projects that are more likely to be progressed have a
well-deﬁned therapeutic margin and detailed understanding of the
agent's adverse toxicity proﬁle. Further, there must be a patient selec-
tion hypothesis and appropriate biomarkers in place. Finally, the project
must target the correct, commercially attractive, patient population. The
5Rs are the pivotal technical determinants of project success.
Applying a 5Rs framework to nanomedicine development requires
deﬁnition of the key relationships between biology and technology:
the inﬂuence of tumour pathophysiology on nanomedicine accumula-
tion, distribution, retention, and efﬁcacy, and the correlation between
delivery system properties and in vivo behaviour. Until now, drug deliv-
ery system engineering has been the priority in nanomedicine research[18]. However, there has been little focus on deﬁning the design of the
nanomedicine based on tumour biology, and optimising nanomedicine
use has been largely empirical. Usingmore clinically relevant models to
test nanomedicines will enable the biology of the target population to
drive the ﬁne-tuning of the system properties. By changing our
approach to nanomedicine development, it will be possible to build
data sets supporting translatable clinical development and patient
pre-selection strategies that will help these effective therapies reach
the right patients.
1.1. Anti-cancer nanomedicines in pre-clinical and clinical development
Anti-cancer nanomedicines in clinical development can be broadly
divided into ﬁve main types: liposomes, polymeric conjugates, poly-
meric nanoparticles, polymeric micelles, and others, although there is
some overlap between categories. Antibody-drug conjugates were con-
sidered outside of the scope of this article, as an important therapeutic
class distinct from the particulate nanomedicine systems discussed
here. Examples of marketed anti-cancer nanomedicines and those in
clinical development are summarised in Table 1.
The majority of approved anti-cancer nanomedicines have been de-
signed to exploit the concept of the EPR effect, with a small subset of
nanomedicines seeking to alter nanomedicine behaviour further with
ligand-mediated targeting (e.g., BIND-014 (BIND Therapeutics; [19])
and MM-302 (Merrimack Pharmaceuticals; [20])) [21]. Generally,
EPR-based therapeutics aim to improve efﬁcacy and tolerability by
changing the pharmacokinetics and biodistribution of the drug. They
can minimise the peak free drug concentration (Cmax) while often in-
creasing the area under the curve in plasma and tumour to provide
prolonged exposure to therapeutic levels of drug at the target. By
achieving the ‘right target’ and ‘right exposure’, several nanomedicines
have conferred a signiﬁcantly enhanced therapeutic index to an existing
therapy or enabled new innovative treatment approaches (e.g.,
CRLX101 (Cerulean; [22]) and AZD2811 nanoparticle (AstraZeneca;
[23])). The AZD2811 nanoparticle employed a novel encapsulation of
an Aurora-B kinase inhibitor to mitigate dose-limiting bone marrow
toxicity in pre-clinical testing and is currently in early clinical trials.
An important beneﬁt of some nanomedicines is the ability to formu-
late a drug without using dose-limiting toxic excipients present in cur-
rent marketed formulations, often improving tolerability and enabling
more drug to be administered to patients. For instance, higher doses
of paclitaxel can be administered to patients using Abraxane™
(Celgene) or the polymeric micelle formulation Genexol-PM™
(Samyang Biopharmaceuticals) because these formulations avoid the
use of Cremophor™ needed to formulate Taxol™. While not considered
to be the major focus for many nanomedicine research projects, such
solubilisation beneﬁts can be considerably cost-effective. Moreover, by
achieving the ‘right safety’ proﬁle, this approach can make a signiﬁcant
difference to the patients and the clinical outcome, as themaximum tol-
erated dose of the active agent can be increased by avoiding the tolera-
bility problems caused by the solubilising surfactants. However,
without improved efﬁcacy, the increased cost of nanomedicine systems
can prevent them from being a mainstream treatment choice. For this
next generation of therapeutics, it is important to engage with
Table 1
Examples of anti-cancer nanomedicines in clinical trials or on the market.
Nanomedicine
type
Drug Product name/company Indication Phase
Liposomes Doxorubicin Myocet™/Teva UK Metastatic breast cancer Approved
Doxil™/Janssen Kaposi's sarcoma
Ovarian cancer (post-ﬁrst line failure)
Multiple myeloma
Approved
ThermoDox™/Celsion Primary hepatocellular carcinoma
Refractory chest wall breast cancer
Colorectal liver metastases
Phase III
Phase II
2B3–101/2-BBB Medicines BV Brain metastases Glioma Phase II
Vincristine Marqibo™/Spectrum Pharmaceuticals Acute lymphoblastic leukaemia Approved
Daunorubicin DaunoXome™/Galen HIV-related Kaposi's sarcoma Approved
Cytarabine Depocyt™/Pacira Pharmaceuticals Lymphomatous meningitis Approved
Irinotecan Onivyde™/Merrimack Pharmaceuticals Metastatic pancreatic cancer (2nd line)
Gastric cancer
Approved
Phase II
Cytarabine: daunorubicin
5:1 ﬁxed ratio
CPX-351/Celator Acute myeloid leukaemia Phase III
Cisplatin Lipoplatin/Regulon Non-small cell lung cancer Phase III
SPI-77/ALZA Pharmaceuticals Ovarian cancer Phase II
Aroplatin/Aronex Pharmaceuticals Malignant mesothelioma Phase II
Oxaliplatin MBP-426/Mebiopharm Gastrointestinal adenocarcinoma Phase II
Paclitaxel LEP—ETU/Insys Breast cancer Phase II
EndoTAG-1/MediGene Breast cancer Phase II
PNU-91934/MSKCC Esophageal cancer Phase II
SN-38 LE-SN38/Neopharm Metastatic colorectal cancer Phase II
Irinotecan: Floxuridine
1:1 ratio
CPX-1/Celator Colorectal cancer Phase II
Polymeric
conjugates
Camptothecin CRLX101 (cyclodextrin adamantane)/Cerulean Renal cancer
Small cell lung cancer
Ovarian cancer
Phase II
Asparaginase Oncaspar™ (PEG)/Baxalta Acute lymphoblastic leukaemia Approved
Paclitaxel Opaxio™ (Polyglycerol adipate)/CTI Biopharma Ovarian cancer
Non-small cell lung cancer (women)
Phase III maintenance
Phase II
Irinotecan NKTR102 (PEG)/Nektar Metastatic breast cancer Phase III
Camptothecin CRLX101 (nanoparticle)/Cerulean Renal cell carcinoma (3rd/4th line)
Ovarian cancer (2nd/3rd line)
Phase II
XMT1001 (Fleximer™)/Mersana Gastric cancer (2nd line)
Non-small cell lung
cancer (2nd/3rd line)
Phase II
Diaminocyclohexane (DACH)
Platinum
AP 5346 (Hydroxypropylmethacrylate)/ProLindac™ Ovarian cancer Phase II
Docetaxel DEP™ (G5 PEG-Polylysine)/StarPharma Advanced cancers Phase I
CriPec™ docetaxel (nanoparticle)/Cristal Therapeutics Solid tumours Phase I
Polymeric
nanoparticles
Docetaxel + Prostate-Speciﬁc
Membrane Antigen (PSMA)
BIND-014 (Accurin™)/BIND Therapeutics Cholangiocarcinoma
Cervical cancer
Bladder cancer
Head and neck cancer
Non-small cell lung cancer subtypes
Phase II
AZD2811 (AZD1152
hydroxyquinazoline pyrazol
anilide; Aurora-B Kinase
Inhibitor)
AZD2811 (Accurin™) nanoparticle/AstraZeneca Advanced solid tumours Phase I
Polymeric
micelles
Paclitaxel Genexol-PM™/Samyang Biopharmaceuticals Breast cancer
Non-small cell lung cancer
Ovarian cancer
Approved
NK105/NanoCarrier™ Stomach cancer
Breast cancer
Phase III
NC-4016/NanoCarrier™ Solid tumours Phase I
Nanoxel™/Samyang Biopharmaceuticals Advanced breast cancer Phase I
DACH-platin NC-6004 Nanoplatin™/NanoCarrier™ Pancreatic cancer
Head and neck cancer
Non-small cell lung cancer
Bladder cancer
Phase III
Other Irinotecan HA-irinotecan HyACT™/Alchemia Colorectal cancer
Lung cancer
Phase II
Phase III
Tumour Necrosis Factor (TNF) CYT-6091/CytImmune Non-small cell lung cancer Phase II
Paclitaxel Abraxane™/Celgene Advanced breast cancer
Advanced non-small cell lung cancer
Advanced pancreatic cancer
Approved
27J.I. Hare et al. / Advanced Drug Delivery Reviews 108 (2017) 25–38
28 J.I. Hare et al. / Advanced Drug Delivery Reviews 108 (2017) 25–38physicians and healthcare providers to demonstrate (what they regard
as) meaningful clinical differentiation.
The nanomedicine ﬁeld has devoted signiﬁcant effort towards devel-
oping insight into the technological and biopharmaceutical advantages
and disadvantages of different nanomedicine systems. Many different
nanomedicines have been developed that improve the stability, solubility,
pharmacokinetics/biodistribution, toxicity, and/or efﬁcacy of cytotoxics
and other classes of payloads [18,24]. Delivery system characteristics
like size, charge, shape, type of surfacemodiﬁcation, and biocompatibility
have an important inﬂuence on the biodistribution and clearance of the
nanomedicine [25–26].
As shown in pre-clinicalmodels and patients, ‘stealth’ nanomedicines,
with prolonged circulation times, are able to achieve considerable accu-
mulation at sites of leaky vasculature [27–32]. In pre-clinical models,
smaller (sub-100 nm) nanomedicine systems and lower molecular
weight macromolecules have been shown to extravasate to a greater
extent and/or penetrate farther from the vasculature than do larger
systems [33–37]. This size effect has also been associated with improved
efﬁcacy [34,37]. However, it is too premature to generalise this size-
dependency, which is likely tumour- and nanomedicine-dependent. The
ability to control the release rate of a drug from a nanomedicine can sig-
niﬁcantly impact its safety and efﬁcacy. Tuning drug release to exploit
the therapeuticwindowcanbe achievedbymodulating diffusion through
a polymer matrix or by using chemical conjugation linkers with different
degradation (e.g., hydrolysis) rates in vivo [23,38–42]. Building clearer in-
sight into the relationship betweendisease biology andnanomedicine be-
haviour will allow data-driven manipulation of the properties of the
delivery system. Focussing nanomedicine development to align a delivery
system, tumour, and drug with a speciﬁc clinical line of sight is discussed
further in Section 3.1.
1.2. Perceived challenges for the nanomedicine ﬁeld
The attrition of anti-cancer agents in clinical trials is high; to improve
success, it is important to learn why. For some nanomedicines, the root
cause of the failure has been investigated. The paclitaxel-polyglutamic
acid conjugate Opaxio™ was tested in phase III clinical trials for the
treatment of non-small cell lung cancer. However, a survival beneﬁt
was only observed for females, but not males, treated with Opaxio™
[43]. Opaxio™ relies on cathepsin B-mediated activation, and since the
clinical trial, a relationship between oestrogen levels and cathepsin B ac-
tivity has been reported [44]. As a result, subsequent clinical studies
with Opaxio™ have been restricted to women with oestrogen levels
above a pre-deﬁned threshold.Fig. 1. Improving the successful clinicWhile Opaxio™ has developed a sound strategy to address the issue
going forward, for most nanomedicines that fail in the clinic, the reason
for the disappointing efﬁcacy or increased toxicity is unknown. More-
over, the biological drivers behind the poor clinical translation are likely
to bemulti-factorial. Further, early stage clinical trials are typically com-
pleted in heavily pre-treated patients presenting with advanced, meta-
static disease, and co-morbidities. Predicting many of these variables
from pre-clinical testing alone is challenging; therefore, interfacing
with the clinicians is important.
As was the case for early antibody therapeutics, the probability of
success with nanomedicines is perceived to be low [9–10,45–47].
Progressing nanomedicines therapeutics to market is often slow. This
may be because their clinical efﬁcacy is not sufﬁcient to warrant accel-
erated development, or that technical or cost challenges in scale-up
andmanufacturing can delay (or necessitate further) investment. How-
ever, the greatest drivers of failure may be our poor understanding of
the disease heterogeneity in the patient population, inability to ﬁne-
tune the system based on the disease biology or stage of the target pa-
tients, and failure to build a platform of evidence supporting a speciﬁc
end clinical application.
This situation should encourage us to optimise and reﬁne how pro-
jects are designed and conducted. To exploit the signiﬁcant advance-
ments in nanomedicine engineering, focussing how nanomedicine
therapeutics are tested clinically is important. Investing in the transla-
tional science will improve clinical outcomes, as it has for other classes
of cancer drugs. Demonstrating improved clinical performance with
nanomedicines will enable them to be broadly established as a credible
and viable drug development option. As highlighted above, traditional-
ly, nanomedicine research projects have been structured to adapt the
physico-chemical parameters of a delivery system – loading, chemistry,
size, charge, surfacemodiﬁcation – to control its in vivobehaviour.What
has been largely lacking is insight into the features of patient tumours
that present unique challenges for nanomedicines to display optimal
performance.
Considerably less research effort has been dedicated to the challenge
of understanding the correlations between patient biology and
nanomedicine behaviour. While for now the nanomedicine ﬁeld is pri-
marily embracing the attractive, but often evidence-lacking, assumption
of a positive correlation between EPR and efﬁcacy [15–16,46,48–50], the
successful clinical translation of nanomedicine projects would be im-
proved by greater focus in four key areas (Fig. 1):
1) Building the understanding of the interaction between tumour path-
ophysiology and nanomedicine behaviour in tumours, to enable theal translation of nanomedicines.
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and retention of distinct nanomedicines
2) Transitioning from formulation-driven research to disease-driven
rational development
3) Developing and exploitingmore clinically relevant animalmodels to
optimise nanomedicine properties, dosing schedules, and treatment
combinations with a clinical line of sight to the target disease as it
develops in patients
4) Pre-selecting patients likely to respond to nanomedicine-based
therapy
Together, drawing on the principles of the 5Rs framework and
implementing these changes in nanomedicine science would underpin
a more precise and an improved translatable approach to nanomedicine
development that adopts a patient-focussed and disease-driven mindset
from the outset.
These four areas are important for improving the successful clinical
translation of nanomedicines; however, prioritising where to focus
investment is also key. This will depend on the speciﬁc challenges in the
development of each novel nanomedicine. Two common scenarios in
nanomedicine development are novel delivery systems with established
drugs and established delivery systems with novel payloads. Developing
a new nanomedicine using a well-characterised delivery system will
beneﬁt from selecting the right patients. Here, the parameters driving
the efﬁcacy of the free drug (concentration versus exposure time) and
the in vivo behaviour and critical quality attributes of the delivery system
affecting in vivo performance should already be understood. Conversely,
when testing a novel delivery system, investment should be focussed to
gain insight into the behaviour of the delivery systemacross a range of tu-
mour models to aid in deﬁning the most suitable clinical populations.
When beginning the development of a novel drug with a novel delivery
system, implementing patient-driven design and building a strong pre-
clinical platform of evidence will be the most advantageous areas in
which to focus investment.
2. The EPR effect in nanomedicine development
The EPR phenomenon elegantly explains the enhanced accumula-
tion and prolonged retention of macromolecules observed in solid
tumours, relative to normal tissue [2–3,51]. The EPR effect has become
a dogma in the literature to explain the targeting of nanomedicines to
tumours after intravenous administration [33]. Despite the fact that
EPR-mediated accumulation has only been reported for some tumour
types [52–53], it is often claimed as a universal property of all solid
tumours and is regularly cited as the driving ‘passive targeting’ principle
underlying most nanomedicine research and development in cancer
[48,54].
However, the EPR effect is unlikely to be present and equal in all tu-
mours, nor likely to be the sole driver of nanomedicine efﬁcacy.
Nanomedicine activity is not only related to tumour accumulation/
retention (EPR effect); it is also inﬂuenced by the intra-tumoural distri-
bution of the delivery system, the extent and kinetics of drug release
within the tumour, and the exposure to drug released in circulation.
The contribution and importance of these elements will vary with the
delivery system, drug, and properties of the tumour, and each must be
considered when optimising nanomedicine systems.
2.1. Measuring nanomedicine biodistribution in patient tumours
The practicalities of evaluating the EPR effect in human tumours are
relatively costly and time-consuming [15,50,55]. However, the potential
rewards of a reliable evaluationmethod couldmake the costs acceptable.
For long-term success, however, investing inmore structured approaches
to assess the EPR effect in pre-clinical and patient tumours would be in-
valuable. At present, it is challenging to complete an in-depth analysis be-
cause the majority of the currently available methodologies for tracingnanomedicines in vivo do not provide sufﬁcient resolution [50]. While
greater detail can be achieved using more sophisticated techniques
(e.g., imaging-based, such as gamma-scintigraphy or dynamic contrast-
enhanced magnetic resonance) [50,55], they require expensive equip-
ment that is often not accessible formany laboratories or hospitals.More-
over, few tracking techniques are useful across a range of delivery systems
[50]. This capability becomes increasingly important when directly com-
paring different delivery systems for their suitability for a speciﬁc clinical
application.
Nanomedicine biodistribution and accumulation in human tumours
have only been documented in a small number of patients by gamma-
scintigraphy/SPECT imaging of indium/technetium-labelled liposomes
[27,53,56–58] and detection of drug ﬂuorescence in patient biopsies
[59]. Tumour accumulation of indium-labelled liposomes varied be-
tween tumour types, from 5± 3% of the injected dose/kg in breast can-
cers to 33 ± 16% of the injected dose/kg in head and neck cancers [56].
These data illustrate the concern that the access and/or accumulation of
the nanomedicinemay be disease-dependent and differ from tumour to
tumour [55–56]. The implications of this concept should not be under-
appreciated. The inter-tumour variability in nanomedicine delivery is
conﬁrmed by a recent analysis of the EPR effect in spontaneous canine
carcinomas and sarcomas that showed substantial heterogeneity in
the level of liposome uptake, as measured by CT/PET scanning [60].
Therefore, if tumour EPR is a driving principle in the design charac-
teristics of a nanomedicine, then it is essential to treat tumours that
present an EPR effect, as obviously variability in the level of EPR effect,
or even a complete lack of an EPR effect, would signiﬁcantly impact
the clinical outcome. Deﬁning the biological conditions driving EPR var-
iability is essential. However, there is currently no systematic investiga-
tion of the magnitude or diversity of the EPR effect in patient tumours,
making patient or tumour type pre-selection challenging at present
and requiring coordinated investment to make it a reality.
2.2. The tumour microenvironment and nanomedicine behaviour
In addition to circulation kinetics, drug release, and tumour
clearance rates, the overall tumour exposure to a nanomedicine and
its payload is governed by entry into the tumour, distribution across,
and retention within the tumour. Human cancers have been shown to
exhibit features (e.g., fenestrated or permeable vasculature, dysfunc-
tional or underdeveloped lymphatic system, and high interstitial ﬂuid
pressure [61–67]) that affect these processes. In human tumours, the
dominant features determining tumour drug exposure are poorly
understood. Moreover, such tumour features may either be polarised
(biased to one or two dominant features), or manifested only subtly.
The EPR effect, and more generally the tumour exposure to a
nanomedicine, is dependent on many more factors than ‘just’ local per-
meability of endothelia lining tumour blood vessels and the prolonged
circulation characteristic of a nanomedicine. The importance of and
interaction between such factors is increasingly being recognised,
including the following:
• tumour—type, size, proliferation rate, necrosis, intra-tumoural
volume, and anatomical location
• vasculature—density, volume, permeability, distribution relative to
stromal and tumour cells, and blood ﬂow
• stroma—architecture, density, composition, and matrix rigidity
• macrophages—number and function
• lymphatics—density, function, and location within and around the
tumour
• interstitial ﬂuid pressure—local effects and cross-tumour pressure
gradients
To gain insight into aspects of the complex tumour biology, we
analysed over 200 different patient tumours from eight different cancer
types. This revealedmarked variability in the vasculature, speciﬁcally its
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as well as in macrophage number and distribution across human
tumours. This variation was observed between tumour types, between
tumours of the same type, and even within individual tumours
(Fig. 2). Nanomedicine scientists often fail to appreciate the signiﬁcance
and implications of this heterogeneity when designing and testing new
formulations. While some consistent trends in tumour features can be
observed between cancers (see Fig. 2), the high degree of variability
even within speciﬁc tumour types makes it critical to evaluate tumour
features together in individual tumours, and to pre-select the ‘right pa-
tients’with a greater likelihood of beneﬁting from nanomedicine-based
therapy.
Tumour histology is not sufﬁcient to predict tumour EPR. More be-
spoke analyses of tumour features using high-resolution imaging can
be employed pre-clinically to gain functional insight into the relation-
ship between the microenvironment and nanomedicine behaviour in
different pre-clinical models that recapitulate the clinical setting.
Several imaging modalities, including CT, multi-spectral optoacoustic
tomography, MRI, and functional ultrasound, have been used to investi-
gate the inﬂuence of tumour vasculature, permeability, perfusion, and/
or interstitial ﬂuid pressure on the magnitude and heterogeneity of
nanomedicine accumulation and intra-tumoural distribution in
pre-clinical models [68–73]. These important studies primarily used
liposomes, and as a major ﬁnding, a strong correlation between vascular-
isation and intra-tumoural accumulation/distribution was noted. This
suggests that tumour vascular density and perfusion may greatly inﬂu-
ence the therapeutic outcome of passively targeted nanomedicine thera-
py. Moreover, the variation in local/regional vessel permeability, blood
volume, and interstitial pressure throughout a tumour will also dictate
the carrier deposition and should be included in expanded analyses
usingmore clinically relevantmodels [15–16,74–76]. These same tumour
features are expected to inﬂuence nanomedicine behaviour in humans.
Therefore, continued investment is required to develop additional clini-
cally relevant imaging techniques that can validate the signiﬁcance of
these parameters in patients.Fig. 2.Heterogeneity in tumour features across human clinical cancers. Representative immunoh
vasculature (CD31; A), stroma (alpha-smooth muscle actin; B), and macrophages (CD68; C). P
colorectal and renal cancers than in ovarian and prostate cancers. Colorectal and prostate c
vasculature was located amidst the tumour cells. A signiﬁcantly higher stromal content was o
lowest macrophage content was observed in prostate tumours. However, it must be noted
disease type.2.3. Why invest in patient pre-selection?
Within large pharma, very early on in drug development projects,
there is a strong focus on the deﬁnition of the ‘right patients’ to treat.
Molecularly targeted therapies have beneﬁted signiﬁcantly from ratio-
nal patient selection strategies and personalised treatment approaches.
Clinical trials with more focus on clearly deﬁned outcome criteria, bio-
marker proﬁles, and treatment schedules have improved results in pa-
tients. A similar strategy in nanomedicine projects could improve
clinical performance.
Identifying a suitable companion diagnostic or clinically useful bio-
marker that is predictive of therapeutic outcome presents a signiﬁcant
challenge, but also a signiﬁcant reward. Selecting the ‘right patients’ is
complex for nanomedicines and other classes of anti-cancer agents.
For instance, remarkably, a therapeutic response to trastuzumab or
cetuximab treatment is not always observed in patients with high tu-
mour expression of HER2 and EGFR, as measured by ex vivo diagnostic
staining. Clearly though, such diagnostic approaches provide important
information but do not guarantee the correct identiﬁcation of the ‘right
patients’ to treat. However, patient pre-selection efforts enable clear
decision-making and serve as a starting point for stratiﬁcation of
treatment groups.
Patient stratiﬁcation strategies are attractive, butmore demanding, for
nanomedicines, as patient pre-selection for both delivery system and
payload must align. Moreover, as tumour pathophysiology varies with
growth and disease stage, selecting the ‘right patients’ for nanomedicinal
therapies requires data-based knowledge of nanomedicine suitability for
each delivery system in individual tumours [55].
2.3.1. Using companion diagnostics to predict treatment outcome
The development of companion diagnostics to screen a patient's
‘nanomedicine suitability’ has received only limited attention so far
[77–78]. A drug-free version of a nanomedicine system labelled with
an imaging agent can be used to identify patients likely to beneﬁt
from the therapeutic version [79]. This requires an understanding ofistochemical staining of humanprostate, ovarian, colorectal, and renal tumourmaterial for
ositive staining represented by brown colour. Greater vascular density was observed in
ancer vasculature was situated in the stromal compartment; ovarian and renal cancer
bserved in prostate and colorectal cancers, compared to ovarian and renal tumours. The
that substantial variability was seen within each tumour and between patients in each
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drug throughout the body, as discussed later. Signiﬁcant cost reductions
and improvements in the speed of generating key data informing pro-
ject progression will be aided by state-of-the-art imaging techniques,
integration with in silico modelling, and advances in bioanalytical
methods for drug and nanomedicine visualisation and quantiﬁcation.
Following a labelled delivery system is most useful when it can be
related to the fate of the drug, based on robust understanding of the ki-
netics of drug release in plasma, and ultimately, in the future, in the tu-
mour and tissues. Further, it is also necessary to deﬁne the parameters
driving anti-cancer efﬁcacy in order to evaluate therapeutic potential,
choose the appropriate patient pre-selection criteria, and deﬁne poten-
tial biomarkers. For instance, if a prolonged duration of exposure is key
to a drug's activity, evaluating the duration of delivery system retention
in the tumour may prove to correlate with treatment outcome. Howev-
er, if a high Cmax drives drug efﬁcacy, it may be more appropriate to
evaluate the peak accumulation of the delivery system, provided that
its release kinetics achieve therapeutic levels of bioavailable drug in
tumour.
Moreover, it may be possible in some circumstances to avoid using a
companion diagnostic nanomedicine, and instead use the accumulation
of small molecules to predict the accumulation of the therapeutic
nanomedicines. Published pre-clinical ﬁndings have shown strong
agreement between the magnitude and intra-tumoural distribution of
the CT enhancement patterns for a CT contrast agent and a liposomal
carrier [70]. Employing clinically relevant imaging techniques to trans-
late this research into a strategy to visualise nanomedicine therapeutics
in patients could transform decision-making early in development.
Karathanasis et al. used a rat model of breast cancer to demonstrate
the feasibility of using mammography to quantify the tumour extrava-
sation of a nanoscale probe in individual tumours to predict therapeutic
beneﬁt of liposomal doxorubicin treatment [76]. A strong correlation
between probe accumulation/extravasation and positive treatment out-
come was observed [76], highlighting the potential utility and impor-
tance of patient pre-selection approaches. Moreover, it suggests that
vascular permeability may be a useful selection parameter to evaluate
in some instances.
Using high-resolution ﬂuorescent imaging of xenograft tumours,
Miller et al. have shown, with 85% accuracy, the co-localisation of two
different nanomedicine delivery systems—amagnetic nanoparticle suit-
able for magnetic resonance-based diagnostics and a polymeric system
designed to deliver therapeutics [80]. Further exploration of the concept
of nanomedicine-based companion diagnostics with other delivery
systems could identify additional “imaging-friendly” nanomedicine sys-
tems useful for predicting the accumulation and localisation of different
therapeutic nanomedicines. However, validation on a case-by-case
basis would be necessary.
2.3.2. Early efforts to apply patient pre-selection and companion diagnos-
tics in the clinic
Merrimack Pharmaceuticals is investing in the use of a companion
diagnostic to identify the patients most likely to beneﬁt from treatment
with their novel liposomal irinotecan formulation. Preliminary experi-
ments utilised magnetic resonance to image the tumour accumulation
of a 30 nm iron oxide nanoparticle (Feraheme™, AMAG Pharmaceuti-
cals) with subsequent assessment of the therapeutic response of the
same patients receiving liposomal irinotecan therapy [81]. Feraheme™
is approved by the FDA for the treatment of iron deﬁciency anaemia.
When employed off-label to evaluate the EPR characteristics of patient
tumours, a strong correlation between Feraheme™ tumour uptake
and shrinkage of tumour lesions following liposomal irinotecan treat-
ment was observed [81].
Despite the difference in size and composition between the two
nanosystems, the data suggest that imaging tumour accumulation of
the iron oxide nanoparticles is a highly useful pre-selection tool for lipo-
somal irinotecan treatment [81]. This approach might be able to begeneralised to other passively targeted nanomedicines as well, if en-
hanced accumulation underpins their therapeutic activity. The potential
translational beneﬁts of such a clinically validated pre-selection tool to
determine broad applicability across tumour types and nanomedicine
systems warrants substantial continued effort.
Beyond patient pre-selection, other nanomedicine-based approaches
to companiondiagnostics are being utilised in the clinic as part of compre-
hensive cancer treatment strategies. For example, Lymphoseek™ is a
mannose-derived dextran conjugate that has been FDA-approved as a ra-
dioactive diagnostic for locating tumour-draining lymph nodes [82–83].
As well, LUM015, a nanoparticle in phase I trials, can be used to identify,
in real time, cancer cells in the tumour margin during surgery [84].
3. Developing nanomedicines using ‘industry-style’ thinking to
enhance clinical translation
Whilst pre-clinical experimentation has been used effectively to gen-
erate proof-of-principle and drive optimisation of new nanomedicine
technologies, it is important to identify weaknesses and remain objective
about their relevance for later development. The primary aimof early pre-
clinical testing should be to identify both the therapeutic potential and
any clinical risks, to select formulations that will be safe and efﬁcacious
and possess the required pharmacokinetic and biodistribution properties.
In the past, anti-cancer nanomedicine research has used the standard
formulation-driven approach: novel nanomedicines are developed and
then evaluated using in vitro cytotoxicity assays, in vivo pharmacokinet-
ics/biodistribution studies, and anti-tumour experiments in xenograft
models sensitive to the payload. This paradigm has not generated the
data that yield insight into the key issues that enable the successful trans-
lation of nanomedicines to the clinic. Instead, using a decision-making
framework like the 5Rs should enable scientists to make ‘go/no-go’ in-
vestment decisions earlier in the development process, before making
signiﬁcant ﬁnancial investment in clinical trials. Realising the need to
change current nanomedicine development strategies, this section
focusses on the goal of disease-driven design and generating pre-clinical
project data that more reliably inform clinically relevant therapeutic end
points, to be implemented in treating the ‘right patients’.
3.1. Adopting a structured approach to nanomedicine projects
No single nanomedicine will achieve the ‘right exposure’ and the
‘right efﬁcacy’ in all tumour types. For large pharma, the range of
nanomedicine systems available at present makes it possible and
favourable to adopt a disease-driven development strategy and transi-
tion away from formulation-driven (bottom-up) approaches. From the
start of the project, it is important to build a clinical line of sight and
to understand the speciﬁc challenges with the standard‐of‐care, such
as excessive normal organ toxicity or unsuitable pharmacokinetic pro-
ﬁle. Designing a nanomedicine to overcome a well-deﬁned challenge
in a particular cancer has a greater chance of success than developing
a delivery system and then attempting to align it with an existing clini-
cal challenge. It is essential to consider the relationship between the
heterogeneous disease and patient pathophysiology and the physico-
chemical properties of different nanomedicines to enable the data-
driven selection of the nanomedicine systems that aremost appropriate
for speciﬁc disease types. Further, this requires the generation of more
informative data in the clinic which can be bridged back to improve de-
velopment strategies.
Thus, rational selection criteria are critical in the development of clin-
ically successful and translatable nanomedicines. A disease-driven ap-
proach to development focusses on aligning a drug, delivery system,
and target patient population to balancemany different variables tomax-
imise therapeutic activity (Fig. 3). For example, human cancers are sensi-
tive to speciﬁc drugs. The physico-chemical properties of different
nanomedicine systems dictate their suitability for delivering certain
drugs, and any off-target effects that may result from the “dose” of the
Fig. 3. Considerations when selecting the delivery system, drug, and target patient population for disease-driven design and development of new anti-cancer nanomedicines.
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trations in patients. Further, the tumour features of the target patient pop-
ulation will inﬂuence the levels of accumulation and retention of the
carrier that can be expected, which will determine whether the system
can achieve the drug release rate required to deliver drug to the tumour
at therapeutic levels/exposures. The off-target accumulation of the carrier
will determine whether it achieves an appropriate safety proﬁle for the
drug, particularly when administered in combination with the typical
standard-of-care regimens for the target cancer. Although complex, con-
sidering these patient- and disease-focussed parameters from the design
phase should produce more translatable nanomedicines.
It is not practical, however, to develop nanomedicines for individual
patients. Using a structured framework, the aim is to focus the develop-
ment of a nanomedicine to a speciﬁc patient population. In-depth knowl-
edge of tumour genetics has generated a translatable patient focus for
therapies targeting speciﬁc genetic drivers. To progress towards patient-
drivennanomedicine design, initial investment is required to build a com-
prehensive understanding of the complex criteria highlighted in Fig. 3.
Such insight will underpin the ability to achieve focussed, accelerated,
and translational development with a clinical line of sight.
After establishing a clinical line of sight, the genetic proﬁle and in-
trinsic sensitivity of the target patient population inﬂuence many deci-
sions. These include choosing the drug itself, selecting the relevant
models for testing, deﬁning the optimal drug release rate (to achieve
the desired high maximum concentration, increased area under the
curve, or improved therapeutic index, etc.), optimising the dosing
schedule, and building combination therapy knowledge. Building this
clinically translatable data set requires a series of focussed experiments
to reﬁne the nanomedicine and sequentially answer clinically relevant
questions about the lead candidate. In vivo studies in realistic models
are even more expensive; therefore, it is important to think carefully
about the value of the data sets generated. Testing models and
nanomedicines representing the extremes of different parameters
(e.g., tumour phenotype or drug release rate) can give broader insight
and enable complementary in silicomodelling approaches to be applied
to reduce overall cost.
3.1.1. Using disease-driven design to achieve the ‘right efﬁcacy’
Disease-driven design is rooted in understanding the implications of
biology for nanomedicine behaviour in order to select a carrier able to
exploit the pathophysiology. Heterogeneity in the tumour microenvi-
ronment between different tumours and cancers presents uniquebarriers to nanomedicine-based treatment, which can be overcome by
some delivery systems but may be problematic for others. As a result,
disease-driven design considers the target patient population from the
outset and works to design the right nanomedicine to exploit the path-
ophysiology. The opportunity to use academic-industry collaborations
to generate these data is discussed in Section 4.2.
For instance, tumour types like pancreatic cancers with complex,
dense stroma, where penetration is severely limited, may be most sus-
ceptible to a small delivery system with a high drug:carrier ratio [34]
or a depot of a sustained-release drug delivery system for an agent
that does not require a high Cmax. These approaches are designed to
overcome the limitations of the tumour biology by increasing penetra-
tion and delivering more drug away from the vasculature, or exploiting
the prolonged retention that is experienced in highly stromal tumours
to achieve greater drug exposure within the tumour. Moreover, in high-
ly stromal phenotypes, combining nanomedicines with therapies
designed to manipulate the tumour microenvironment may have the
potential to overcome the physiological barriers that limit the therapeu-
tic effect of some nanomedicines [85–88]. Nanomedicinal therapeutics
may beneﬁt from combination approaches with hyaluronidase
[89–90], from degradation of collagen [91] or inhibition of its synthesis
[92] or cross-linking [93], and from vascular normalisation [94].
Renal cancers, and some other highly vascularised tumours, present
with the tumour cells in close proximity to the blood vessels; these tu-
mours may exhibit a more classical enhanced accumulation effect, but
the retention of the carrier may be reduced or limited to the periphery.
Here, to achieve the ‘right exposure’, it may be necessary to employ a
nanomedicine with a sufﬁciently rapid drug release rate that the payload
becomes bioavailable before the delivery system is cleared from the tu-
mour. Thus, slow release nanomedicines may not be optimal for tumour
types where prolonged delivery system retention is unlikely. Alternative-
ly, attaching a targeting ligand to the carrier may be able to improve its
retention [95] to overcome this issue. Finally, in tumourswith a highmac-
rophage content, exploiting themononuclear phagocytic systembecomes
a possibility, as does exploring immune-oncology therapies or combina-
tions. These examples highlight the potential advantages of aligning an
appropriate nanomedicine to the biology of a speciﬁc target population.
3.1.2. Using patient-focussed design to achieve the ‘right safety’
Understanding the off-target effects of nanomedicines is as impor-
tant as evaluating efﬁcacy. Nanomedicines will distribute into all tissues
exhibiting the features, such as fenestrated vasculature, which permit
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controlling the tissue localisation, particularly within the reticuloendo-
thelial system, of different delivery systems is of equal importance to
the assessment of the tumoural drug accumulation to increase efﬁcacy.
A recent paper from Kirtane et al. illustrates how a predictive model of
size-related carrier accumulation can help us gain broader insight into
nanomedicine behaviour and generate experimental hypotheses to
test [96]. The model in this paper highlights that the EPR effect is not
necessarily the key driver of beneﬁt for every nanomedicine and pro-
poses that the size of the delivery system is dictated by the features of
the tumour, in particular the pore size [96].
Further, the levels of drug present in different target and off-target
organs are controlled by the release rate of the drug from the delivery
system, and the relative clearance from tumour versus normal tissues
[96]. The importance of understanding therapeutic index is exempliﬁed
by the development of AstraZeneca's AZD2811, an Aurora-B kinase in-
hibitor delivered using a BIND Therapeutics Accurin™ polymeric nano-
particle. During pre-clinical development, the drug release rate from the
nanoparticle was exploited to minimise bone marrow toxicity with
therapeutic drug exposure. Nanoparticleswith signiﬁcantly different re-
lease rates showed equivalent efﬁcacy in a rat xenograft model, but
substantially different levels of bone marrow toxicity [97–98]. The
importance of release rate has also been demonstrated in different
scenarios, including by Hu et al. [42].
Knowledge of the activity and toxicities of the free drug, the behav-
iour of different delivery systems, and anunderstanding of the inﬂuence
of drug release rate on target and off-target concentrations of bioavail-
able drug enable project teams to select an appropriate range of
nanomedicines to test. A small amount of improvement in translational
success through rational nanomedicine design would justify the initial
investment required to build these essential baseline data sets. Howev-
er, a key element of this change is further investment in broader strate-
gic collaborations [16].
Reﬁning basicmodels of nanomedicine behaviour by incorporating in-
dividual tumour types and normal tissues would signiﬁcantly improve
decisionmaking when progressing nanomedicinal therapeutics. Deﬁning
these parameters across the nanomedicine toolbox provides an opportu-
nity to match a delivery system with a suitable distribution proﬁle to a
speciﬁc drug's toxicity proﬁle in an appropriate disease setting. This is
particularly applicable when designing a nanomedicine to overcome a
known problem—for instance, doxorubicin-induced cardiotoxicity limits
the cumulative dose a patient can receive. By administering doxorubicin
in a liposomal formulation, the cardiac exposure is eliminated or dramat-
ically reduced, allowing patients to be treatedwith higher life-time doses.
Moreover, well-tolerated nanomedicines like Doxil™ can be highly
beneﬁcial in combination regimens, to improve tolerability or enable
the combination partners to be delivered at higher doses.
The off-target toxicities of nanomedicines may be different than
the parent drug, as a result of the change in pharmacokinetics and
biodistribution. An example of this is the risk of palmar-plantar
erythrodysesthesia during Doxil™ therapy [99–100], in comparison to
the cardiotoxicity of the free drug. Understanding the nanomedicine
properties, dose, and scheduling parameters that deliver efﬁcacy, as
well as toxicity, enables more informed design of the clinical plan,
drug combination opportunities, and population selection.
3.2. Building a stronger platform of evidence to justify project progression
EPR effect-based tumour accumulation is typically the primary focus
during nanomedicine development. However, in some tumour types,
nanomedicine accumulation is only minimal or highly variable, while
altering the peripheral plasma pharmacokinetics of the drug can also
yield therapeutic beneﬁt. Thus, to evaluate nanomedicine efﬁcacy,
pre-clinical researchneeds to generate data sets that describe four prop-
erties of nanomedicine behaviour: the tumoural accumulation, intra-
tumoural distribution, and tumoural retention of the system, as wellas the additional contribution of the peripheral pharmacokinetics (or
circulation) of the nanomedicine. It is likely that for any tumour, each
of these features may independently contribute to potential efﬁcacy;
however, the dominant feature can inﬂuence the choice of delivery
system and release kinetics desired. Further, as discussed above, under-
standing the off-target effects is as important as evaluating efﬁcacy
when taking a nanomedicine into development.
Translatable pre-clinical testing should strive to provide detailed
insight into the key parameters that inﬂuence nanomedicine efﬁcacy.
Informative and translatable data sets should consider the following:
• Characterise the intra-tumoural carrier retention, drug release rates,
and drug metabolism over time
• Differentiate between bioavailable/released drug and total concentra-
tions of drug in the tumour, plasma, and other key organs (e.g., liver,
bone marrow, etc.)
• Deﬁne the intra-tumoural distribution of therapeutically active
concentrations of bioavailable drug and drug metabolites
• Understand how the plasma, off-target tissue, and tumour pharmaco-
kinetics of the nanomedicine are affected by repeat dosing
• Separate the evaluation of pharmacokinetics/biodistribution from
efﬁcacy/mechanism of action
• Evaluate treatment efﬁcacy in tumours having reached less EPR-rich
sizes
• Understand the degree of therapeutic beneﬁt from extravasation
versus simple accumulation/residence in the tumour vasculature
versus alteration of the pharmacokinetics of the drug
• Evaluate the inter-tumour variation within a group
• Maintain clear focus on the end clinical application (such as combina-
tion with standard-of-care) of the nanomedicine;
• Evaluate its efﬁcacy in that context to deﬁne an appropriate dose and
schedule
While it is easy to list a set of activities, it has to be recognised that it
is currently technically difﬁcult to generate insight into these questions,
particularly across delivery systems. Many imaging approaches label
and follow the distribution of the delivery system (agnostic of the fate
of the associated drug). To improve our understanding, we need to con-
sider the release, trafﬁcking, and target engagement of the payload
which ultimately exerts the therapeutic effect. Further, it is important
to invest in developing and reﬁning the necessary analytical approaches
because the ability to determine the concentration of bioavailable versus
bound/encapsulated drug throughout the body is fundamental to many
of the considerations listed above. Itmay only be possible to achieve these
complex data sets through more strategic collaborations. Once in place,
the data packages that can be produced during nanomedicine develop-
ment will be substantially more informative and discriminatory when
selecting lead candidates andwhen progressing to the clinic. Maintaining
a clear focus on the end clinical application and building a thorough un-
derstanding of the therapeutic margin of novel nanomedicines are likely
to have a signiﬁcant impact on improving translation.
3.3. Enhancing nanomedicine translation by using more clinically relevant
models
Many of the ﬁrst pre-clinical nanomedicine development projects
were driven by data generated in sensitive subcutaneously implanted
cell line-derived xenograft models [24]. The translatability of these re-
sults to the clinic has limitations, as the majority of these tumour lines
present pathologies that bear little resemblance to the complexity and
heterogeneity of the clinical tumours they are presumed to model
[101–105]. This research has supported the conclusion that EPR-based
efﬁcacy should occur across all human tumours, and the drug delivery
ﬁeld has been founded on this belief. Further, relative to most clinical
solid tumours, nanomedicine accumulation and intra-tumoural
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models are highly vascularised, rapidly proliferating, have a high level
of macrophage inﬁltrate, and possess a simple stromal architecture
and low stromal density. Optimising nanomedicines to achieve efﬁcacy
in these types of models may not produce therapies that are effective in
treating human solid tumours.
The in vivo models we rely on for developing new nanomedicines
may only reﬂect a narrow spectrum of the human pathophysiology.
Pre-clinical testing with liposomal doxorubicin shows that animal efﬁ-
cacy can be predictive of suitability for treating a speciﬁc clinical tumour
phenotype closely reﬂecting the pathophysiology or histology of the
models. For instance, early research demonstrated the efﬁcacy of liposo-
mal doxorubicin in tumours with a high tumour cell density, low stro-
mal content, and dense and highly permeable vascularisation. These
observations have successfully translated to the clinic, where Doxil™
has shown its greatest therapeutic efﬁcacy in the treatment of multiple
myeloma and AIDS-related Kaposi's sarcoma [24].
Past oncology research has relied on generating data in accessible
pre-clinical models that often do not recapitulate the patient tumour
features [106]. This is particularly problematic for therapies whose
intra-tumoural behaviour and therapeutic efﬁcacy are inﬂuenced
by tumour heterogeneity and morphology, such as biologics and
nanomedicines. The extent of pre-clinical testing completed in poorly
representative models is a signiﬁcant and often ignored obstacle for
translating nanomedicine research. It is important to recognise that
these pre-clinical data drive important clinical decisions, such as dose,
schedule, and the expectation of efﬁcacy. Striving to represent the target
patient tumour population better will allow informed investment
decisions. It is now possible to determine how well our in vivomodels
recapitulate human cancers by accessing tumour biobanks in collabora-
tion with major oncology centres to characterise the genetics, patho-
physiology, and heterogeneity of patient tumours.
Routine generation of data sets in a diverse panel ofmodels that rep-
resent aspects of the target clinical tumour population is essential.
Aligning the activity of a drug and a delivery system inmodels represen-
tative of the genetic proﬁle of the target patient population, as well as
the suitability of the delivery system in a speciﬁc tumour pathophysiol-
ogy, often requires multiple pre-clinical models. This ensures that the
proﬁle of the system selected for further development is more broadly
applicable across the tumour type, rather than optimised for one indi-
vidual animal model.
More importantly, highlighting potential limitations earlymay inform
on a ‘stop decision’ for a project before signiﬁcant investment is required,
or constrain the type of patients treated in early trials. Once the desired
physico-chemical and biological characteristics of a nanomedicine are de-
ﬁned, it is then possible to use pre-clinical models to assess progress. For
example, if the aim is to generate a formulation for a drug already known
to be clinically active, then failure to show activity in multiple models of
that disease type drives a stop decision. Conversely, toxicity concerns
revealed by pre-clinical testing in relevantmodelsmay also drive stop de-
cisions. For instance, beyond a certain threshold, some delivery systems
can lead to additional adverse effects by virtue of their clearance proper-
ties, such as deposition in the liver and spleen with long-term effects on
these organs upon repeat dosing. Finally, establishing the therapeutic
index with agents the nanomedicine is likely to be combined with in
the clinic can inform on the likelihood of success in early clinical trials.
These objectives can be deﬁned at the start of a programme, and have
proven critical in improving success for classical therapeutics. The ability
tomake these decisions early in the pre-clinical testing phase is an essen-
tial part of cost-effective development of nanomedicines, and all other
anti-cancer therapeutics.
3.3.1. The beneﬁts of using more clinically relevant models
Patient-derived tumour explant (PDX) models and genetically
engineered mouse models (GEMMs) more faithfully reﬂect the mor-
phology, complexity, and heterogeneity of clinical tumours [102–103,107]. Although PDX models are difﬁcult to establish and resource-
intensive to maintain, due to the typical slow growth rate and require-
ment for live passaging to help to maintain the clinical pathology,
there are now thousands of models available through both contract re-
search organisations and academic institutions. Likewise, GEMMs have
similar drawbacks, but offer the potential to assess how nanomedicines
achieve efﬁcacy in tumours residing in speciﬁc organs (e.g., liver versus
lung). While the models may not be directly predictive of the clinic,
they all have features that enable the assessment of the performance
of a given nanomedicine, and generate insight into risks. A number of
studies have now been published using these more relevant models to
develop new perspectives on nanomedicines.
As mentioned, further insight can be developed by using GEMMs,
where the tumour develops in situ. The Zamboni group recently pub-
lished a paper that used GEMMs as relevant models of different breast
cancer subtypes and showed that the components of the tumourmicro-
environment contributed to the heterogeneity of liposome, but not
small molecule, accumulation in the tumour [108]. As more clinically
relevant and diverse models become increasingly accessible to
nanomedicine researchers, the ability to perform more realistic assess-
ments of nanomedicine accumulation, intra-tumoural distribution,
and retention will be highly valuable in generating a platform of evi-
dence for the activity of different types of nanomedicines across tumour
(pheno)types.
The vasculature in clinical tumours and many PDX models is more
mature and less permeable than in xenografts, which develop over
days, rather than weeks or months, and present properties that are
less inﬂuenced by the overall rate of tumour cell proliferation [48,
102]. Further, in the majority of human tumour types, vessels are
found either within the stromal compartment or in close proximity to
tumour cells [109]. This differential vessel distribution is more faithfully
recapitulated in PDX models [110] and is expected to inﬂuence
nanomedicine behaviour in solid tumours. Assessing a number of differ-
ent models with varied vessel distributions, as well as assessing
tumour-to-tumour variation, is required to build amore realistic under-
standing of the likely outcome in different human disease segments.
3.3.2. Greater variety is possible with more clinically relevant models
Pre-clinical tumours are often considered to be uniform. However,
sufﬁciently complex pre-clinical models can capture the inﬂuence of tu-
mour heterogeneity andmorphology on nanomedicine efﬁcacy. Using a
single PDX model that presented with a spectrum of stromal morphol-
ogies, detailed analysis showed that tumour architecture signiﬁcantly
impacts nanomedicine treatment outcome, in a cohort of tumours
possessing the same intrinsic sensitivity [111]. Rather than reporting
group means, capturing the variability in pharmacodynamic effect
between individual tumours provides insight into the diversity in
response possible within human disease segments. Particularly as
tumours change with disease stage and in response to therapy, this
proof-of-principle study highlights the importance of striving to devel-
op biomarkers and imaging tools that enable patient pre-selection
strategies.
A study of the distribution and activity of liposomal irinotecan (pro-
drug of SN-38) demonstrated that therapeutic efﬁcacy was inﬂuenced
by the accumulation of active drug in the tumour through enhanced
vascular permeability and the presence of the enzyme that generates
the active drug SN-38 [107]. The authors also showed that retention of
active SN-38was higher in tumour cell-derived xenografts than tumour
cell explants [107]. This may imply that liposomes accumulate better in
xenograft models derived from cells lines, and when models with a
complex microenvironment are used, a different conclusion may be
drawn. This study analysed the formulation across a panel of 13models
[107] and highlights that exploring more diverse models will yield
valuable insight. Determining how tumour features are associated
with reduced efﬁcacy or drug penetration may inform a clinical plan,
particularly when considering the potential inﬂuence of tumour
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in the study by Kalra et al. [107] gives broader insight into the potential
of liposomal irinotecan and hence a data platform that helps focus the
development and target population strategy.
4. Pharma perspective
A number of challenging questions are often asked of oncology pro-
jects: Why is the pre-clinical testing of anti-cancer agents so poor at
predicting their clinical potential? Why is there a disconnect between
animal models of cancer and human patients? What factors must be
considered pre-clinically to improve success clinically? Project teams
need to deﬁne the tumour type and stage, dose and dosing schedule,
and potential currently used drugs with which the novel agent may be
combined. As the project matures, they are also asked to articulate
clearly the risks that may hinder clinical success. Although hard to
address, some answers to these questions are required to improve the
translation of oncology therapeutics and secure larger investment.
To make a project attractive for pharma to take into development,
theremust be an opportunity to test a focussed hypothesis, and the abil-
ity to make a decision on whether the agent is likely to succeed with a
minimal initial investment. As discussed above, projects are progressed
when there is conﬁdence in the 5Rs: ‘right target/efﬁcacy’, ‘right tissue/
exposure’, ‘right safety’, ‘right patients’, and ‘right commercial potential’
[17]. This general approach has been shown to improve success for pro-
jects to develop classical small molecules [17].
4.1. The cost of success … and failure
The probability of success of a small molecule drug progressing from
pre-clinical proof-of-principle to commercial launch is in the region
of 6% [17]. There is a continuing demand for innovative, patient-
personalised therapeutics to improve clinical outcomes. Nanomedicines
have a tremendous potential to achieve this goal. However, industry,
correctly or incorrectly, sees additional challenges when considering
investment in nanomedicines, and other classes of therapeutics like
antibodies, peptides, and DNA-/RNA-based agents. For these agents,
the formulations are often more complex; there is poor understanding
of the correlation between critical quality attributes and efﬁcacy; the
regulatory perceptions and environment are constantly evolving;
manufacturing and scale-up are technically challenging; important ana-
lyticalmethods require furthermaturation; and the cost of goods is high
(up to 15% higher than for tablets and standard parenterals). A key con-
sideration when adopting nanomedicinal therapies is the cost–beneﬁt
provided by the nanomedicinal drug versus the cheaper (often generic)
therapy. However, if such approaches can be delivered cost-effectively
with the ‘right commercial potential’, the advantages should not be
undervalued.
As a result, the development costs for novel classes of therapeutics
can be disproportionately high. Moreover, with a lack of in vitro and
pre-clinical tests to predict performance in man adequately, it requires
a substantial investment to frontload formulation and process optimisa-
tion to avoid repeating long complex clinical studies. Looking to the
future, rather than using nanomedicines to develop a solution to formu-
late the drug, it may bemore rational to develop nanomedicine-friendly
active pharmaceutical ingredients. For instance, it is possible for syn-
thetic chemists to engineer speciﬁc features into the design of novel
small molecules to develop drugs that aremore compatible for conjuga-
tion, active-loading, encapsulation, or complexationwith nanomedicine
technologies.
For any company, but in particular smaller biotech companies or ac-
ademic labs, the expense of taking a prototype nanomedicine into the
clinic and beyond can be prohibitive. For large pharma, this cost can
be a major blocker for investment, due to a lower perceived probability
of success with added technical complexity potentially compounding
the risk already associated with a novel drug. Therefore, the pre-clinical data sets supporting a nanomedicine therapeutic need to be
stronger compared to those associated with classic drug therapeutics,
which have more conventional formulations, deﬁned patient
populations, and fewer treatment obstacles.4.2. Collaborations are essential to the future success of nanomedicines
The development of nanomedicinal therapeutics is a multidisciplin-
ary endeavour. Like many areas of drug development, it requires the
successful integration of biology, chemistry, nanotechnology, imaging,
and medicine. However, the diversity and complexity in nanomedicine
systems necessitates highly varied expertise to develop translatable
therapeutics. As such, it will become important to foster partnerships
between large pharma, smaller companies, and academia early in pre-
clinical development to capitalise on the unique strengths of each
partner.
Effective collaborations between academia, industry, consortia, and
cancer research hospitals will be essential to build the data sets and in-
sight that link the physico-chemical properties of nanomedicine systems
with biological implications. The Nanotechnology Characterisation
Laboratory (NCL; www.ncl.cancer.gov) is a multidisciplinary laboratory
set up in 2004 by the National Cancer Institute, National Institute of
Standards and Technology, and FDA. The NCL's remit is to support the
pre-clinical characterisation of nanomaterial-based drug delivery prod-
ucts. This includes establishing and standardising an analytical cascade
for nanomaterial characterisation and facilitating the clinical develop-
ment and regulatory review of nanomaterials for cancer clinical trials.
The aim to provide robust nanomedicine charactrisation extends to the
identiﬁcation and characterisation of the critical parameters related to a
nanomaterial's absorption, distribution, metabolism, and excretion
(collectively termed ADME) and toxicity. As part of its effort, the NCL
engages with and facilitates academic and industry-based knowledge
sharing and interfaces with regulatory authorities. A European
Nanomedicine Characterisation Laboratory (EU-NCL; www.euncl.eu)
was set up 2015 with similar aims to the NCL.
Other consortia have also been established in Europe. These include
the European Technology Platform for Nanomedicine (ETPN; www.etp-
nanomedicine.eu), created in 2006, and more recently a Translational
Advisory Board, which is part of the EU ENATRANS project (Enabling
NAnomedicine TRANSlation; www.enatrans.eu). They aim to provide
free of charge, non-binding, and strategic advice to promote and guide
projects in the nanomedicine area.
The additional advantages of collaborative working are that new
methods can be developed for improved characterisation, and testing
in more than one lab or set of models improves the robustness, speed
of data generation, and diversity of the platform of evidence. We are
seeing the start of collaborative working with the National Cancer
Institute's Alliance for Nanotechnology in Cancer, which has formed an
expert public-private partnership between academia, government,
and industry to accelerate nanotechnology development and transla-
tion. In 2012, the Translation of Nanotechnology in Cancer (TONIC) con-
sortiummet to discuss the importance of improving the “understanding
of the EPR characteristics impacting the utility of nanoparticles in the
clinic” [16].
Working consortia and expert collaborations like TONIC and EU
ENATRANS have the potential to exploit the diverse expertise of their
members to achieve signiﬁcant progress in answering the major ques-
tions presently facing nanomedicine scientists. Broader collaboration
has additional beneﬁts. Valuable insight could be derived from compar-
ing the efﬁcacy or accumulation/intra-tumoural distribution of new
nanomedicines against “benchmark” formulations (such as Doxil™),
similar formulations, and different delivery systemswith the same pay-
load. This type of collaboratively generated information becomes highly
informative to companies seeking to make investment decisions be-
tween different delivery systems and exploit disease-focussed design.
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Many of the nanomedicine formulations in development and clinical
trials are designed for cytotoxics, where broadening the therapeutic
window can address issueswith tolerability or sub-optimal target expo-
sure that may limit the ability to develop the drug into a viable and ef-
fective product [40,100,112]. Future opportunities for nanomedicines
are looking towards delivering the next generation of drugs:molecular-
ly targeted agents, toxin-like agents that induce cell death, DNA‐/RNA-
based therapeutics, peptides, drug combinations, etc. Themajor delivery
challenges for these agents include signiﬁcant off-target accumulation,
crossing the cell membrane, achieving synergistic drug ratios at the tar-
get, and a narrow therapeutic window. Turning these “undeliverable”
next generation therapies into viable anti-cancer treatments has
emerged as one of the main future directions for nanomedicines. The
cost-effective delivery of nucleic acid-based therapeutics requires
unique nanomedicine technology and knowledge, and some companies
are making a focussed investment in this area, including Alnylam
Pharmaceuticals, Calando Pharmaceuticals, Avidity NanoMedicines,
Merck, and Arrowhead Research Corporation.
The standard practise of formulation-driven development has not
achieved the expected patient beneﬁt; however, nanomedicines still
have the potential to enter the mainstream of cancer therapeutics,
both for traditional and next generation agents. While scientists have
attempted to overcome the challenges in achieving efﬁcacy in patients
by developing and investigating an overwhelming number of new
nanomedicines, relatively few of the many promising pre-clinical
nanomedicines have reached the market. There are important gaps in
the translation of nanomedicines, and it is necessary to shift some of
the long-established paradigms to overcome these hurdles.
Although poor clinical translation is also a concern with other classes
of anti-cancer agents, at present, the costs of taking a novel nanomedicine
into the clinic can be a signiﬁcant obstacle. The best way to make
nanomedicines cost-effective is to increase the probability that the pa-
tientswho are treatedwill respond to the therapy, using focussed design
anda decision-making strategy like the 5Rs framework.Moreover,with-
out developing, validating, and implementing patient pre-selection
tools, it will remain challenging to achieve the right cost-efﬁciency for
nanomedicine therapeutics. Although not without its own challenges,
a concerted effort across the nanomedicine ﬁeld to adopt new and
more clinically focussed ways of working will help the next wave of
nanomedicines to address the obstacles, perceived or real, encountered
in the current clinical trials. Investing in the science underpinning the
fundamental principles in nanomedicine science could have a signiﬁcant
impact on bringing efﬁcacious nanomedicine therapies to patients.
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